Promega Expands NanoLuc mRNA Access via UBC Partnership

Event summary

Promega has authorized the University of British Columbia's RNA & Formulation Core to manufacture and distribute NanoLuc-encoding mRNA constructs.
NanoLuc luciferase is a highly sensitive bioluminescent reporter, producing signals over 150x brighter than conventional systems.
The agreement aims to streamline access for researchers in LNP delivery optimization, mRNA vaccine development, and gene therapy applications.
Distribution is authorized for research use only, available immediately through the UBC RNA & Formulation Core.

The big picture

This partnership aligns with the rapid expansion of mRNA and lipid nanoparticle (LNP) research since the COVID-19 pandemic. By simplifying access to NanoLuc-encoding mRNA, Promega and UBC are addressing a key bottleneck in optimizing mRNA delivery systems. The deal underscores the growing importance of bioluminescent reporters in therapeutic development, particularly for applications requiring precise measurement of mRNA expression.

What we're watching

Market Adoption: How quickly academic and commercial labs will integrate NanoLuc-encoding mRNA into their workflows.
Competitive Positioning: Whether Promega can maintain its lead in bioluminescent reporter technology amid growing demand for mRNA research tools.
Regulatory Landscape: The pace at which regulatory frameworks evolve to support advanced mRNA and LNP delivery systems.